2017-06-22 09:26 ET - News Release

Mr. Boris Ziger reports

MATICA APPROVES FINAL PLANS TO INCLUDE INCREASED PRODUCTION CAPACITY

Matica Enterprises Inc. and RoyalMax Biotechnology Canada Inc.'s management have met with the general contractor, the subcontractors and other consultants at the Dorval facility. In late May, Health Canada announced improvements to the access to cannabis for medical purposes regulations application process to permit licensed producers to manage production on the basis of their vault capacity. Matica and RoyalMax have doubled the designed vault size to accommodate a significant increase in their production capacity.

With the new improvements to the ACMPR application process, the stages of the process have been altered. The prelicence inspection stage has been removed and the licence to produce is now issued upon confirmation of completion of the facility. Matica and RoyalMax have now completed the final preparations required for the completion of the Dorval facility.

We seek Safe Harbor.